About Us      Management Team      Boards of Directors      Scientific Advisory and Consultant      Company Culture

Xiaoqiang Yan, Ph.D.
Chairman, CEO
Dr. Yan has 30 years of biopharmaceutical industry experience in new drug discovery and development with therapeutic focuses in hematology, oncology, autoimmune, and metabolic diseases. He first discovered the none pro-inflammatory properties of interleukin 22 (IL-22), designed and produced a recombinant human IL-22 dimer (F-652), and successfully translated the protective biology of IL-22 during inflammatory tissue damage to a novel biological drug. The significant clinical efficacy and excellent safety profile of the drug was demonstrated in acute graft versus host disease (GvHD) and acute alcoholic hepatitis phase IIa clinical trials. Dr. Yan built and led multiple teams following NMPA/FDA/EMA regulations and guidance, and successfully developed multiple first-in-class — and best-in-class — biological drugs from structure design, cell line development, and pre-clinical development. He conducted first-in-man clinical studies and global multicenter phase II/III clinical trials reaching expected clinical endpoints, including cGMP drug manufacturing. He is a successful serial biotech entrepreneur with more than 200 granted patents as a co-inventor and has over 30 scientific publications.
Ex-Chairman, CEO, CSO, co-founder of Generon Corporation Ltd. (Shanghai). Ex-VP, Research & Technology, Hutchison Medipharma Ltd. Research Scientist I, II III, Department of Function Genomics, Pharmacology & Pathology, and Experimental Hematology, Amgen Inc. USA. Ph.D. in Molecular & Cell Biology, Department of Medical Biophysics, University of Toronto, Canada. Master and Bachelor of Medicine, West China University of Medicine, Sichuan, China.

Hanyang Chen, Ph.D.
CTO(Chief Technology Officer)
Dr. Chen has more than 15 years of experience in new drug discovery and development. He is an expert in biological assay development and validation, bioanalytical method development and validation, in vivo pharmacology, pharmacokinetics, GLP toxicity studies, and translation medicine and biomarkers. Dr. Chen is also involved in more than 20 new drug candidates including small molecules and biologicals, and has built and led an outstanding team, successfully achieved goals with multiple challenging projects, and developed and validated bioanalytical methods according to FDA guidance that were able to quantitate biologicals at pg/mL levels. He made significant contributions to the global clinical phase II/III filing and the FDA BLA filing.

Former senior director at Generon Corporation Ltd. (Shanghai), responsible for bioanalytical, analytical, and quality controls. Former senior research scientist, at Hutchison Medipharma Ltd, responsible for drug screening platform establishment and new drug discovery in oncology.

Guiyun Tu, MSc
Head of antibody engineering
Msc Bioengineering Fujian Normal University. Over 15-year of experience in new drug discovery including the design and optimization of fusion recombinant protein (Fc-dimer) and bispecific antibody platform structure design, drug screening, and recombinant protein production, stable cell line generation. With a successful track record in developing a number of novel iTAb bi-specific and multi-specific antibodies.

Wuzhong Shen, M.D.
Head of in vitro biology
Graduated from Medical college, Xi An Jiao Tong University. Responsible for in vitro biological and translational research.Over 17-year experience in new drug R&D including small molecules, T cell engagers, cytokines and other large molecules.Participated in writing Module 2 and 4 in IND and BLA applications.Worked in the pathophysiology department of Shanghai Jiao Tong University School of Medicine on the pathogenesis of leukemia for 4 years.

Zheng Yang, Ph.D.
Head of in vivo biology
Ph.D in Biomedical Sciences University of Macau. Over 10-year experience in drug R&D and CRO industry, with hands-on experiences in biology, pharmacology, disease animal models, pharmacokinetics, drug safety evaluation, IND filing as well as project management in FDA BLA filing.

Guojian Yu, MSc
Head of drug manufacturing
Msc Clinical Veterinary Jilin University. Over 10-year experience in recombinant protein manufacturing. Participated 2 NMPA BLA applications and 2 on-site GMP inspections by NMPA, and 5 phase I IND filing. A sound track record in cell culture and purification process development, pilot scale manufacturing and GMP manufacturing.

Pingsheng Tian, MSc
Patent Attorney
With 19 years rich experiences in the IP and R & D of biopharmaceutical industry, Successfully managing the patent applications in China and global markets. He used to charge of the reviews to make the applications granted. He was the principal representative in the patent arbitration for the company.He is a master in biochemistry at the University of Otago, New Zealand.

Xing Zhao, M.D.
Head of clinical operation
Graduated from Chengdu Medical college. Physician for 8 years involving different specialties including internal medicine, respiratory, hematology and oncology. Over 4-year experience in clinical trials worked for CRO and sponsors involved in clinical operation, medical writing, QA/QC.Conducted clinical trials in patients with liver cancer, lung cancer, thyroid carcinoma, breast cancer, stroke, ALL and lymphoma.

Copyright © 2021 ITabMed Co., Ltd. All Rights Reserved